Redhill Biopharma (NASDAQ:RDHL) Stock Crosses Below 200-Day Moving Average – Should You Sell?

Redhill Biopharma Ltd. (NASDAQ:RDHL)’s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.83 and traded as low as $0.65. Redhill Biopharma shares last traded at $0.65, with a volume of 400,699 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Redhill Biopharma in a research note on Monday, August 3rd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Redhill Biopharma Price Performance

The stock has a 50-day simple moving average of $0.67 and a 200 day simple moving average of $0.82. The company has a market capitalization of $3.97 million, a PE ratio of 0.00 and a beta of 4.96.

Institutional Investors Weigh In On Redhill Biopharma

An institutional investor recently raised its stake in Redhill Biopharma stock. Gagnon Securities LLC raised its holdings in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) by 383.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,102 shares of the biotechnology company’s stock after acquiring an additional 68,280 shares during the quarter. Gagnon Securities LLC owned approximately 1.68% of Redhill Biopharma worth $89,000 as of its most recent filing with the Securities and Exchange Commission. 7.20% of the stock is owned by institutional investors.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.